stockrowImmunovant, Inc.
IMVT Healthcare Biotechnology
- EPS
- −5.63%
- Free cash flow
- −5.96%
Quarter to June 2026, against a year earlier
Follow IMVT
Alert me
Immunovant, Inc. (IMVT) Return on invested capital
Immunovant, Inc.'s return on invested capital over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2026 (0.00%). Over the past ten years it has ranged from −5,018.5% (fiscal 2019) to 0.00% (fiscal 2026) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2026 | 0.00% | 0.00 |
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 5,018.54 |
| FY2019 | −5,018.5% | (5,018.54) |
| FY2018 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | 17.7% |
| LGND Ligand Pharmaceuticals Incorporated compare | 1.27% |
| KOD Kodiak Sciences Inc. compare | 0.00% |
| IONS Ionis Pharmaceuticals, Inc. compare | 0.00% |
| IMVT Immunovant, Inc. | 0.00% |
| MANE Veradermics Incorporated compare | 0.00% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −9.55% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −184.7% |
| CGON CG Oncology, Inc. compare | −4,111.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)